Trial Profile
A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nidufexor (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 29 Aug 2020 Primary endpoint (Change From Baseline in Alanine Aminotransferase (ALT) Levels) has been met.
- 29 Aug 2020 Results presented at The International Liver Congress 2020
- 22 Jan 2020 Status changed from completed to discontinued.